IP Library Granted Patent US 7,118,562
Granted Patent B2
US 7,118,562 · App. 10/631,213 · Granted Oct 10, 2006

Laser system and method for treatment of biologic targets

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,118,562
App. No.
10/631,213
Granted
Oct 10, 2006
Kind
B2
Abstract

A long pulse alexandrite laser for treating dermatological specimens is disclosed. The use of alexandrite allows operation in the near-infrared, specifically in a 50 nm range surrounding 755. Infrared in this range allows good penetration while still achieving an acceptable ratio of hemoglobin to melanin absorption In addition, a method and related system for treating biologic tissue with pulse light includes generating a long effective output light pulse comprising a series of sub-pulses having a fractional duty cycle over a selected effective pulse duration, a periodicity that is less than the thermal relaxation time of a targeted structure, and an interpulse-delay between successive sub-pulses that is greater than the thermal relaxation time of non-targeted structures within the treatment area; and delivering the output light to the tissue of a patient.

Claims (12)

1. A method for wearing biologic tissue with pulse light, comprising:

generating a long effective output light pulse comprising a series of sub-pulses having a fractional duty cycle over a selected effective pulse duration, a periodicity that is less than the thermal relaxation time of a targeted structure, and an interpulse-delay between successive sub-pulses that is greater than the thermal relaxation time of non-targeted structures within the treatment area, the targeted structures being substantially adjacent to the non-targeted structures within the treatment area; and

delivering the output light to the tissue of a patient.

2. The method as described in claim 1 wherein the output light pulse comprises a laser light pulse.

3. The method as described in claim 1 wherein the effective pulse duration is approximately equal to the thermal relaxation time of the targeted structure.

4. The method as described in claim 1 wherein the targeted structure comprises blood vessels.

5. The method as described in claim 4 wherein the targeted blood vessels are larger than 30 microns in diameter.

6. The method as described in claim 1 wherein the effective pulse duration is larger than 0.1 msec.

7. The method as described in claim 1 wherein the effective pulse duration is larger than 0.5 msec.

8. The method as described in claim 1 wherein the effective pulse duration is larger than 5 msec.

9. The method as described in claim 1 wherein the effective pulse duration is larger than 50 msec.

10. The method as described in claim 1 wherein the non-targeted structures include nonnal-sized blood-vessels.

Assignments (2)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 044123/0353 Recorded Apr 23, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED; CYNOSURE, LLC, AS SUCCESSOR-BY-CONVERSION TO CYNOSURE, INC.; CYTYC CORPORATION, AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC
Reel/Frame 075515/0446 →
SECURITY INTEREST Recorded Nov 14, 2017
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; CYNOSURE, INC.; BIOLUCENT, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 044123/0353 →